# Healthspan Capital

> Healthspan Capital is a VC fund backing Biotechnology and Biopharma. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: El Cerrito, United States
- Total investments: 18
- Last investment: Mar 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/healthspan-capital/
- X (Twitter): https://twitter.com/healthspancap
- Website: https://www.healthspancapital.vc/

Healthspan Capital is a venture capital firm that invest and support longevity biotechnology companies.

## Contacts

5 contacts available for Healthspan Capital. Shizune tracks 1 team members at Healthspan Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/healthspan-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 72% |
| Biopharma | 5 | 28% |
| Health Care | 5 | 28% |
| Medical | 2 | 11% |
| Life Science | 2 | 11% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 12 | 67% |
| Series A | 3 | 17% |
| Venture - Series Unknown | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 56% |
| Germany | 1 | 6% |
| Switzerland | 1 | 6% |
| United Kingdom | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Sebastian Brunemeier | Co-founder & General Partner | 3 | https://shizune.co/investors/profile/sebastian-aguiar |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ImmuneBridge | ImmuneBridge is developing allogeneic immunotherapies for cancer. ImmuneBridge's key innovation fosters the development of immune stem cells obtained from cord blood and creates a fresh, adaptable, reliable, and plentiful cellular source for immunotherapies. They are currently looking for natural killer cell-based treatments for hematologicalcancers. They will then attack solid tumors using the special benefits of their cellular source. | $7.7M | Seed | Mar 23, 2026 |  |
| Vincere Biosciences | Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $5M | Series A | Apr 01, 2025 |  |
| ImmuneAGE Bio | ImmuneAGE Bio is an intriguing initiative focused on drug discovery for immune system rejuvenation. Developing therapies that can rejuvenate or enhance the immune system could have profound implications for healthcare, especially in aging populations or those with compromised immune function | $2M | Seed | Jul 11, 2024 |  |
| Reservoir Neuroscience | Reservoir Neuroscience is a biopharma company that develops novel therapeutics to repair dysfunctional blood vessels in the brain. Reservoir Neuroscience was founded in 2019 and is based in Emeryville, California. | $4M | Venture - Series Unknown | Jan 18, 2024 |  |
| KetoSwiss | KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem. | $800K | Seed | Aug 04, 2023 |  |
| Repair Biotechnologies | Repair Biotechnologies is a developer of clinical gene and protein therapies intended to focus on the reversal of age-associated thymic atrophy and consequent loss of immune function. The company's platform is committed to developing treatments for ageing and age-related diseases that address the root causes of these conditions, enabling humanbeings to improve their health span through targeting the causes of age-related diseases and ageing itself. | $8.4M | Seed | Jun 15, 2023 |  |
| Deciduous Therapeutics | Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune-modulatory therapies that clear senescent cells and promote a healthy lifespan. Deciduous is led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, a five-time biotech founder. | $10M | Seed | Dec 31, 2022 |  |
| KetoSwiss | KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem. | $4M | Seed | Oct 13, 2022 |  |
| Samsara Therapeutics | Samsara Therapeutics, Inc. is an R&D-stage biopharmaceutical platform company aiming to discover, develop and commercialize therapeutics for the treatment of unmet medical needs and age-related diseases. Samsara's platform is a pipeline for the identification, chemical optimization, and in vivo validation of compounds that extend a healthylifespan. |  | Series A | Sep 06, 2022 |  |
| Molecule | Molecule is a software platform used to decentralise intellectual property development in the biotech industry. The company was founded in 2020 by Paul Kohlhaas and Tyler Golato and is headquartered in Schaffhausen, Switzerland. | $12.7M | Seed | Jun 13, 2022 |  |

10 of 18 investments shown.

## Co-investors
- [R42 Group](https://shizune.co/investors/profile/r42-group) — VC Fund, 3 deals together
- [Baszucki Group](https://shizune.co/investors/profile/baszucki-group) — VC Fund, 2 deals together
- [Boost VC](https://shizune.co/investors/profile/boostfunder) — VC Fund, 2 deals together
- [LongGame](https://shizune.co/investors/profile/longgame) — VC Fund, 2 deals together
- [ORTHO INNOVATIONS](https://shizune.co/investors/profile/ortho-innovations) — VC Fund, 2 deals together
- [The William K. Warren Foundation](https://shizune.co/investors/profile/the-william-k-warren-foundation) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Switzerland](https://shizune.co/investors/medical-vc-funds-switzerland)
- [Biotechnology Investors in Switzerland](https://shizune.co/investors/biotechnology-investors-switzerland)
- [Biotech Investors in Switzerland](https://shizune.co/investors/biotech-investors-switzerland)
- [Biotechnology VC Funds in Switzerland](https://shizune.co/investors/biotechnology-vc-funds-switzerland)
- [Biotech VC Funds in Switzerland](https://shizune.co/investors/biotech-vc-funds-switzerland)

## FAQ

### What does Healthspan Capital invest in?

Healthspan Capital invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Seed and Series A stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Healthspan Capital?

Public channels for Healthspan Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Healthspan Capital?

The team at Healthspan Capital includes Sebastian Brunemeier (Co-founder & General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co